6
KLBF0312.TXT

KLBF
Kalbe Farma Tbk
Af          :
Sector Code : 53
Sector Name : PHARMACEUTICALS

(In thousand rupiah except Par Value, Closing Price and Ratios)

Financial Statement Date    : 31-Dec-2003
Fiscal Year Ends            : Dec
Months Covered in Income St : 12

Summary of Balance Sheet
  Receivables               :     547,151,425.12
  Inventories               :     305,613,925.30
  Current Assets            :   1,820,973,572.18
  Fixed Assets              :     520,374,422.30
  Other Asstes              :       4,925,643.16
  Total Assets              :   2,448,390,202.89
  Current Liabilities       :   1,161,321,160.94
  Longterm Liabiities       :     263,574,415.47
  Total Liabilities         :   1,424,895,576.40
  Authorized                :      17,000,000.00
  Paid-up Capital           :     406,080,000.00
  Par Value                 :                 50
  Paid-up Capital Shares    :       8,121,600.00
  Retained Earnings         :     380,175,880.13
  Total Equity              :     828,957,856.34
  Minority Interest         :     194,536,770.15

Summary of Income Statement
  Total Sales               :   2,889,209,192.88
  Cost of Good Sold         :   1,265,320,871.11
  Gross Profit              :   1,623,888,321.77
  Operating Profit          :     566,335,240.16
  Other Income              :     -32,387,381.75
  Eearning Before Tax       :     533,947,858.41
  Tax                       :     161,135,219.48
  Net Income                :     322,884,550.89
  Closing Price             :           1,000.00

Per Share Data (Rp)
  Eps                       :              39.76
  Book Value                :             102.07

Financial Ratios
  Debt Equity Ratio (X)     :               1.72
  Roa (%)                   :              13.19
  Roe (%)                   :              38.95
  Npm (%)                   :              11.18
  Opm (%)                   :              19.60

Cash Flow
  CF from Operating Activities                        :     507,168,022.37
  CF from Investing Activities                        :    -397,248,982.32
  CF from Financing Activities                        :      -9,754,727.22
  Net Increase in Cash & Cash Equivalent              :      82,314,315.38
  Cash & Cash Equivalent at The Beginning of The Year :     428,444,489.55
  Cash & Cash Equivalent at The End of The Year       :     510,758,804.93

 
 
 
